[Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
作者信息
Campanella G, Pennetta R
出版信息
Acta Neurol (Napoli). 1974 May-Jun;29(3):252-63.
PMID:4417098
Abstract
摘要
相似文献
1
[Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].[左旋多巴加RO 4-4602联合治疗帕金森病的经验]
Acta Neurol (Napoli). 1974 May-Jun;29(3):252-63.
2
[Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].[左旋多巴-苄丝肼组合对帕金森病的长期治疗结果]
Riv Neurol. 1974 Sep-Oct;44(5):303-30.
3
[CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].[CB 154治疗帕金森病。与左旋多巴和脱羧酶抑制剂联合使用的结果]
Acta Neurol (Napoli). 1976 Jul-Aug;31(4):479-48.
4
[The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].左旋多巴与Ro 4-4602联合治疗帕金森病（作者译）
Riv Patol Nerv Ment. 1974 Oct;95(5):673-5.
5
[Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].[左旋多巴-苄丝肼控释制剂与帕金森病治疗期间疗效的变化]
Rev Neurol (Paris). 1987;143(11):746-52.
6
[Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].[联合用药（左旋多巴加脱羧酶抑制剂（Ro 8-0576））治疗帕金森病的经验]
Wien Med Wochenschr. 1973 Jun 30;123(26):433-5.
7
8
[Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].左旋多巴与脱羧酶抑制剂治疗帕金森综合征
Arch Invest Med (Mex). 1974;5(2):105-16.
9
引用本文的文献
1
Crystal structure of 2,2'-oxybis(4-methylquinoline).2,2'-氧联二(4-甲基喹啉)的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Jan 17;71(Pt 2):180-3. doi: 10.1107/S2056989015000717. eCollection 2015 Feb 1.
2
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.左旋多巴及左旋多巴+RO 4-4602治疗的帕金森病患者临床症状、脑脊液中高香草酸（HVA）和5-羟吲哚乙酸（5-HIAA）与血浆左旋多巴的相关性
Eur J Clin Pharmacol. 1977 Apr 20;11(4):255-61. doi: 10.1007/BF00607673.
Zotero 插件